Modafinilo Viatris

Modafinil, the active ingredient in Modafinilo Viatris, is a eugeroic presented as a unknown/unknown for oral use. It treats excessive daytime sleepiness associated with narcolepsy, obstructive sleep apnea, and shift work disorder, helping patients maintain alertness during waking hours.

GNH USA supplies Modafinilo Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Modafinil acts on central nervous system pathways that regulate wakefulness, providing therapeutic benefit in several sleep‑related disorders.

- Narcolepsy: reduces daytime sleepiness and improves sustained alertness. - Obstructive sleep apnea‑related excessive daytime sleepiness: supports wakefulness when used alongside standard apnea therapy. - Shift work disorder: alleviates sleepiness during scheduled work periods, enhancing functional performance.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Headache - Nausea - Insomnia - Anxiety - Dizziness - Dry mouth

Serious or Rare Side Effects: - Severe skin reactions such as Stevens‑Johnson syndrome - Psychiatric events including psychosis or mania - Cardiac arrhythmias - Hepatic injury - Allergic reactions with swelling or difficulty breathing - Persistent hypertension

When prescribing Modafinil, clinicians should consider several safety aspects.

- Assess cardiovascular status: evaluate blood pressure and heart disease before use. - Review psychiatric history: risk of anxiety, agitation, or emergence of mania. - Avoid in severe hepatic impairment: dose adjustment or contraindication may be required. - Use caution with concomitant CNS stimulants: may increase stimulant‑related effects. - Discuss pregnancy and breastfeeding risks with the prescriber. - Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Modafinil can interact with a range of medications, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may raise modafinil plasma levels. - CNS depressants (e.g., benzodiazepines, alcohol): may diminish wake‑promoting effect. - MAO inhibitors: risk of hypertensive crisis.

Moderate Interactions (Monitor Closely): - Oral contraceptives: may lower hormonal efficacy. - Antihypertensives: potential attenuation of blood‑pressure control. - Antiepileptic drugs (e.g., carbamazepine): may reduce modafinil concentrations.